Tagged with P

USA A comprehensive list of the US FDA’s Center for Drug Evaluation & Research (CDER)’s new drug therapy approvals for 2022. CDER approved 37 new drugs in 2022, down from 50 in 2021, either as new molecular entities (NMEs) under New Drug Applications (NDAs), or as new therapeutic biologics under Biologics…

Greece Takeda’s Cornelia Zanetti, a recent implant into Greece following stints in Germany, Switzerland, and Singapore, shares her first impressions of the Greek pharma market, and how the Japanese giant is making a difference for Greek patients in oncology, gastroenterology, plasma-derived therapies, and rare diseases. Zanetti also highlights some of the…

Greece One of Greece’s leading domestic pharmaceutical companies, RAFARM has had a stellar recent history, including a momentous entry into the US market. Now looking to establish itself as one of Europe’s major players in ophthalmics and complex injectables, VP Aris Mitsopoulos outlines his ambitious growth plan for the firm and…

India The latest news from the Indian pharma industry, including WHO’s recommendation not to use cough syrup from Marion Biotech after further deaths, Indegene’s expanded presence in Europe, Sun Pharma’s FDA warning and the lab partnership between Sai Life Sciences and Schrödinger.   WHO recommends not using Marion Biotech cough syrups…

Africa Diabetes is a significant, and growing, problem in Africa, making access to insulin products a regional imperative. Some important progress is being made, including a new deal between US giant Eli Lilly and Egyptian group EVA Pharma. The agreement will allow Lilly products to be manufactured in, and for, the…

Europe Edward Mc Gettrick and Sharon Gorman of Pfizer, writing in the January 2023 edition of DIA’s Global Forum magazine, examine the scope and impact of the European Union’s new Regulation on Health Technology Assessment.   In December 2021, the European Commission (EC) adopted the Regulation on Health Technology Assessment (EU HTA…

Japan MSD KK’s Fumitaka Noji, writing in the January 2023 edition of DIA’s Global Forum magazine, outlines some of the key upgrades that Japan’s innovation ecosystem needs to become globally competitive once again, namely around strategy and information, investment, and finding qualified experts.   Although the importance of open innovation in…

Greece Fresh from the recent announcement of a massive EUR 356 million investment package for the 2021-2027 period to expand and modernise its production and R&D footprints, DEMO Pharma’s Dimitris Demos outlines how the family-owned firm rode out the financial crisis years and what is powering its growth today. Demos also…

Greece The European Union’s decision to mitigate the effects of the COVID-19 pandemic by launching its Recovery and Resilience Facility (RRF) and moving away from its past austerity policies is particularly significant for Greece. Severely hit by the financial crisis a decade ago and thrown off its course to recovery by…

Global Brendan Shaw looks ahead to the rest of 2023, identifying five key trends to watch out for in the healthcare and life sciences sector. With the worst of COVID-19 now in the rear-view mirror for much of the world, Shaw questions whether the lessons and progress that the pandemic brought…

Egypt The leading company in the Egyptian pharma market by volume, the Egyptian International Pharmaceutical Industries Company (EIPICO) is now making a region-first move into biologicals and biosimilars manufacturing to power its future growth as well as expanding its international footprint.   Biologics: A Big Leap Forward The company’s plan to…

Egypt As the largest pharma market in MEA in terms of volume and second only behind Saudi in value, Egypt is an increasingly important part of pharma multinationals’ MEA operations. Here, three regional managers give their takes on what Egypt means to their companies, and their hopes for its future development.…